Headlines about Cellect Biotechnology (NASDAQ:APOP) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellect Biotechnology earned a news impact score of 0.23 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.3194371513913 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Several equities research analysts have recently issued reports on the company. ValuEngine raised Cellect Biotechnology from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price (up from $12.00) on shares of Cellect Biotechnology in a research report on Monday, September 25th.

Shares of Cellect Biotechnology (APOP) opened at $7.75 on Tuesday. Cellect Biotechnology has a 12-month low of $2.30 and a 12-month high of $13.50.

COPYRIGHT VIOLATION NOTICE: “Cellect Biotechnology (APOP) Earning Somewhat Positive Press Coverage, Analysis Shows” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/11/21/cellect-biotechnology-apop-earning-somewhat-positive-press-coverage-analysis-shows.html.

Cellect Biotechnology Company Profile

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Insider Buying and Selling by Quarter for Cellect Biotechnology (NASDAQ:APOP)

Receive News & Ratings for Cellect Biotechnology Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.